FDA Approves Opdivo in Metastatic Melanoma

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri

As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.

October 16, 2026

By Sara Willa Ernst and Paul Goldberg

Conversation with The Cancer Letter

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

October 16, 2026

By Claire Marie Porter and Paul Goldberg

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

A Fox Chase Cancer Center team is combining a rare longitudinal family cohort, whole-genome sequencing, AI-guided analysis, and laboratory validation to investigate why people with similar inherited susceptibility can experience very different cancer outcomes.

October 16, 2026

By Fox Chase Cancer Center

Cancer Policy

Letai announces: NCI met FY26 goal of full funding payout

In a post on NCI’s LinkedIn, NCI Director Anthony Letai confirmed that the institute has fully awarded and paid out all of its grant funding for the Fiscal Year 2026.

October 16, 2026

By Claire Marie Porter

Cancer Policy

FDA launches Rare Disease Framework Initiative for drug development

FDA announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.

October 16, 2026

Cancer Policy

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

FDA is requesting nominations by Dec. 14 for voting members to serve on the Tobacco Products Scientific Advisory Committee.

October 16, 2026

FDA Approves Opdivo in Metastatic Melanoma

YOU MAY BE INTERESTED IN

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

Letai announces: NCI met FY26 goal of full funding payout

FDA launches Rare Disease Framework Initiative for drug development

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

Renew today!

Subscriber content

Never miss an issue!

Login

FDA Approves Opdivo in Metastatic Melanoma

YOU MAY BE INTERESTED IN

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDsCenter directors are strategizing for likely FDA approval of GRAIL’s Galleri

As trust in USPSTF erodes, cancer screening is in perilDavid Ransohoff predicts a “Wild West” era without evidence-based screening guidelines

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

Letai announces: NCI met FY26 goal of full funding payout

FDA launches Rare Disease Framework Initiative for drug development

FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members

Never miss an issue!

Login

VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri

As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines